CAR T-Cell Therapies for Hematologic Malignancies Moving Toward the Clinic – Targeted Oncology
|
CAR T-Cell Therapies for Hematologic Malignancies Moving Toward the Clinic
Targeted Oncology Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refrac- tory acute lymphoblastic leukemia (R/R ALL). J Clin Oncol. 2017;35(suppl; abstr 3024). Locke FL … Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography – Trends, Analysis … |
